Discussion
Risvodetinib, an oral therapy Abli Therapeutics is developing for people with Parkinson’s disease, reduced multiple disease-related biomarkers, the company announced. The findings come from an expanded analysis of the 201 Phase 2 study (NCT05424276), which enrolled patients with bradykinesia (slowed movement), a hallmark symptom of Parkinson’s. The trial tested…
